Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Conditions
Interventions
Telavancin
Vancomycin or antistaphylococcal penicillin
Locations
1
United States
eStudy Site, 3450 Bonita Road, Ste 201
Chula Vista, California, United States
Start Date
June 1, 2003
Primary Completion Date
January 1, 2004
Completion Date
January 1, 2004
Last Updated
January 16, 2019
NCT05761080
NCT06162052
NCT06596434
NCT06814717
NCT02822768
NCT07312513
Lead Sponsor
Cumberland Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions